Tao Zhong - Shanghai Pharmaceuticals Board VP
| SHPMY Stock | USD 7.88 0.32 3.90% |
Insider
Tao Zhong is Board VP of Shanghai Pharmaceuticals Holding
| Age | 51 |
| Phone | 86 21 6373 0908 |
| Web | https://www.sphchina.com |
Shanghai Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0281 % which means that it generated a profit of $0.0281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1024 %, meaning that it generated $0.1024 on every $100 dollars invested by stockholders. Shanghai Pharmaceuticals' management efficiency ratios could be used to measure how well Shanghai Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nancy Avila | McKesson | 57 | |
| Deborah Weitzman | Cardinal Health | 59 | |
| Napoleon Rutledge | McKesson | 52 | |
| Jessica Mayer | Cardinal Health | 55 | |
| Tammy Gomez | Owens Minor | N/A | |
| Tim Rogan | Patterson Companies | 53 | |
| David Myers | Owens Minor | N/A | |
| Tracy Faber | McKesson | 52 | |
| Brad Lerman | McKesson | 63 | |
| Nicholas II | Owens Minor | 53 | |
| Linda Mantia | McKesson | 52 | |
| Maria Martinez | McKesson | 62 | |
| Dean Scarborough | Cardinal Health | 64 | |
| Kenneth Smith | Owens Minor | 40 | |
| Graham Stanley | Henry Schein | N/A | |
| Sheri Edison | Cardinal Health | 63 | |
| Tom Rodgers | McKesson | 49 | |
| Aster Angagaw | Owens Minor | 57 | |
| Kevin Emerson | McKesson | 51 | |
| Dave Lardy | Patterson Companies | N/A | |
| Stephen Klemash | Owens Minor | 60 | |
Management Performance
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 |
Shanghai Pharmaceuticals Leadership Team
Elected by the shareholders, the Shanghai Pharmaceuticals' board of directors comprises two types of representatives: Shanghai Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shanghai. The board's role is to monitor Shanghai Pharmaceuticals' management team and ensure that shareholders' interests are well served. Shanghai Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shanghai Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yongzhong Li, Vice President | ||
| Ying Ke, Director Center | ||
| Tao Zhong, Board VP | ||
| Man Cho, Pres Director | ||
| Jinqi Yu, G Mang | ||
| Shunjiang Yu, Chief Officer | ||
| Shui ACS, Joint Sec | ||
| Bo Shen, CFO and Joint Company Secretary | ||
| Linqiong Dong, Securities Representative |
Shanghai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Shanghai Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 9.42 B | |||
| Shares Outstanding | 739.51 M | |||
| Price To Earning | 5.42 X | |||
| Price To Book | 0.69 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 215.82 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Shanghai Pink Sheet Analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.